10-Q: SSII Reports Strong Revenue Growth Amidst Going Concern

SS Innovations International, Inc. reported significant revenue growth and reduced net losses for Q2 and H1 2025, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 121.8% to $10,000,305, up from $4,509,126 in the prior year period.
• Net loss for the three months ended June 30, 2025, significantly decreased by 93.8% to $(256,691) from $(4,140,570) in the same period last year.
• Gross profit for the three months ended June 30, 2025, surged by 311.4% to $5,915,058, compared to $1,437,786 in the prior year, driven by decreased raw material prices and manufacturing process improvements.
• For the six months ended June 30, 2025, total revenue grew by 85.6% to $15,120,915, up from $8,146,819 in the previous year.
• Net loss for the six months ended June 30, 2025, decreased by 57.6% to $(5,938,044) from $(13,982,323) in the prior year period.
• The company sold 8 surgical robotic systems in Q2 2025 and 25 systems in H1 2025.
• Cash and cash equivalents increased significantly to $11,375,265 as of June 30, 2025, from $466,500 as of December 31, 2024.
• The company reported a working capital surplus of $31,175,418 as of June 30, 2025.
• Material weaknesses in internal control over financial reporting were identified, including inadequate controls for U.S. GAAP application, lack of written documentation, and insufficient segregation of duties.

Sentiment

Score: 4

Explanation: While the company demonstrates strong revenue growth and a significant reduction in net losses, indicating operational improvement, the explicit 'going concern' warning, continued reliance on related-party financing, and identified material weaknesses in internal controls present substantial financial and governance risks. The positive operational momentum is overshadowed by these fundamental concerns.

Positives

• Total revenue for the three months ended June 30, 2025, more than doubled, increasing by 121.8% to $10,000,305.
• Net loss for the three months ended June 30, 2025, was substantially reduced by 93.8% to $(256,691).
• Gross profit margin significantly improved due to decreases in raw material prices and enhancements in manufacturing processes.
• The company successfully uplisted to the NASDAQ Stock Market LLC, with common shares commencing trading under the ticker symbol SSII effective April 25, 2025.
• Cash and cash equivalents saw a substantial increase to $11,375,265 as of June 30, 2025, from $466,500 at year-end 2024.
• Stock compensation expense decreased significantly by 33.3% for the three-month period and 58.0% for the six-month period, primarily due to reversals for resigned employees.

Negatives

• The company reported an accumulated deficit of $49,600,593 as of June 30, 2025.
• Net cash used in operating activities increased to $(9,555,703) for the six months ended June 30, 2025, indicating higher cash burn from operations.
• Selling, general and administrative (SG&A) expenses increased by 52.7% for the three-month period and 30.5% for the six-month period, partly due to NASDAQ uplisting and legal fees.
• The company recognized income tax expense of $353,729 for the first time in its Indian operations, indicating a shift from prior tax loss positions.
• The company remains dependent on related parties to fund operations and does not expect existing cash resources and income to be sufficient for the next twelve months.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to accumulated deficit and reliance on external funding.
• There are no committed sources of funding, and no assurances that additional funding will be secured when needed.
• Inability to obtain financing could force the company to curtail expansion plans, research and development, and marketing activities.
• Any successful additional financing is likely to substantially dilute current shareholders.
• Material weaknesses in internal control over financial reporting exist, including inadequate controls for U.S. GAAP application, lack of written documentation, and insufficient segregation of duties.
• Litigation is subject to inherent uncertainties, and an adverse result in any legal matter may harm the company's business.

Future Outlook

Management believes it will be successful in its capital formation and planned expansion of operating activities, but there is no assurance that the company will be able to raise additional equity capital or achieve profitability. The company plans to raise additional capital through further private or public offerings in 2025 to scale up operations, incur capital expenditure for in-house machining and tooling, and continue financing research and development in surgical robotics.

Management Comments

• The increase in revenue is primarily due to an increase in the number of SSI Mantra 3 surgical robotic systems and instruments sold.
• The increase in gross profit margin was on account of decreases in raw material prices and improvements in manufacturing processes.
• Research and development efforts in the current quarter were focused on routine product enhancements, involving relatively lower expenditure compared to the previous quarter's development of Mantra 3.0.
• The substantial decrease in stock compensation expense is primarily due to reversal of expenses relating to resigned employees.
• The increase in SG&A expenses is primarily due to higher legal and underwriting fees, increased expenses associated with the company's uplisting to NASDAQ, and business events.
• The increase in interest income is related to fixed deposits, offset by an increase in interest expense on bank overdraft facilities and convertible notes.
• The recognition of income tax expense in Indian operations for the first time is due to sufficient taxable profits, leading to utilization of previously unrecognized deferred tax assets.
• The company is still in its initial years of revenue generation and has not yet established consistent operational revenue cash flows to meet all its fixed operating costs, and hence may continue to incur losses for some time.

Industry Context

The company operates in the surgical robotics industry, which is experiencing increasing awareness of the benefits of robotically assisted surgery, reduced learning curves for robotic surgeons, and growing recognition of robotically assisted surgeries as an approved treatment modality from an insurance coverage perspective. The company's strategy focuses on affordability and accessibility, particularly in underserved regions, leveraging manufacturing operations in India for significant operating cost advantages in production.

Management Changes

Corporate Governance

Legal Proceedings

• The company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm the company's business.

Related Party Transactions

• The company raised $28,000,000 in January 2025 from its affiliate, Sushruta Pvt Ltd., through One-Year 7% Convertible Promissory Notes.
• In February 2025, the company repaid $4,212,637 to Sushruta Pvt Ltd. for five 7% One-Year Promissory Notes totaling $4,000,000, along with interest.
• In February 2025, the company converted Convertible Notes worth $22,000,000, along with accrued interest, issued to Sushruta Pvt Ltd. into 16,046,814 common shares.
• In March 2025, the company converted Convertible Notes worth $8,000,000, along with accrued interest, issued to Sushruta Pvt Ltd. into 5,811,554 common shares.
• Dr. Sudhir Prem Srivastava, through his holding company Sushruta, provided significant financing and is considered the ultimate beneficial owner for certain balances.
• Expenses were incurred on behalf of affiliates including Srivastava Robotic Surgery Pvt Ltd, SS International Centre for Robotics Surgery Pvt Ltd, Sudhir Srivastava Medical Innovations Pvt Ltd, and Telegnosis Private Limited.
• Expenses were incurred on behalf of the company by Sudhir Prem Srivastava, Barry F. Cohen, and Dr. Frederic H Moll.
• Stock compensation expenses and consultancy charges were paid to related parties including Anup Sethi, Barry F. Cohen, Dr. S.P. Somashekhar, Sudhir Prem Srivastava, Vishwajyoti P. Srivastava, M.D., and Arvind Palaniappan.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and the conversion of existing convertible notes.
• Shareholders are exposed to significant risk due to the 'going concern' uncertainty and material weaknesses in internal controls.
• Employees may be impacted by changes in stock compensation plans and potential operational curtailments if additional funding is not secured.
• Customers may benefit from the company's focus on affordable and accessible surgical robotic technology, but potential operational limitations could affect service delivery.
• Creditors (including related parties) are involved in significant financing arrangements, with some debt converted to equity.

Next Steps

• Management is making efforts to raise further funding to scale up operations and meet longer-term capital needs.
• The company plans to raise additional capital through further private or public offerings in 2025.
• Remediation of material weaknesses in internal control over financial reporting is ongoing, including enhancing review processes, engaging external experts, and implementing a cloud-based ERP system.

Key Dates

Recommendation

While SS Innovations International, Inc. demonstrates impressive revenue growth and a significant reduction in net losses, indicating strong market traction for its surgical robotic systems, the explicit 'going concern' warning and heavy reliance on related-party financing present fundamental financial stability risks. The identified material weaknesses in internal controls over financial reporting are also a serious concern, potentially impacting the reliability of financial information. For existing investors, holding may be justified if they believe in the long-term potential of the product and the company's ability to resolve its financial and governance challenges. However, new investors should approach with extreme caution due to the high-risk profile associated with the going concern uncertainty and internal control deficiencies.

Keywords

Surgical Robotics, SSi Mantra, Medical Devices, Healthcare Technology, SEC Filing, 10-Q, Financial Results, NASDAQ, Robotics, India Manufacturing